We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Lydia Meyer-Turkson is Cambridge MA based and has 20 years experience in business development focused on cancer drug discovery, biomarkers and in vitro diagnostics, managing commercial teams in Europe and US. She held Vice President roles at Evotec AG and Epistem Ltd. As Strategic Business Consultant to Horizon Discovery Ltd she was in the team that acquired and then grew the company's first US investment a combination high throughput screening group formerly part of Zalicus based in Cambridge MA. Lydia holds a Bachelor of Science and Masters degree in chemistry from University College Cardiff, Wales and is a Fellow of the Royal Society of Chemistry. Her MBA is from Manchester Business School. She has coauthored numerous abstracts and poster presentations at AACR and ASCO conferences.
At Diacarta developed the commercial strategy and leads it's execution for the company's flagship development product QuantiDNA™ RadTox.
This speaker's sessions: